New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 16, 2014
07:30 EDTBMYBristol-Myers long-term thesis 'entirely unchanged,' says Citigroup
Citigroup said its long-term thesis on shares of Bristol-Myers is "entirely unchanged" after the stock sold off yesterday following safety and efficacy data for Yervoy plus nivolumab. Citi says it has always assumed minimal Yervoy combo use in lung cancer. It reiterates a Buy rating on the stock with a $60 price target.
News For BMY From The Last 14 Days
Check below for free stories on BMY the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
August 18, 2014
07:57 EDTBMYCambridge Healthtech Institute to hold a summit
6th Annual Bioprocessing Summit to be held in Boston on August 18-22.
August 8, 2014
10:03 EDTBMYBristol-Myers Hodgkin lymphoma treatment granted orphan drug status
Subscribe for More Information
August 7, 2014
11:02 EDTBMYBristol-Myers enters development pact with Leica Biosystem
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use